A Game-Changing New Treatment Just Arrived for One of the Deadliest Cancers — Here’s Why Doctors Are so Excited
6 Articles
6 Articles
A game-changing new treatment just arrived for one of the deadliest cancers — here’s why doctors are so excited
The third-leading cause of cancer death in the US, pancreatic cancer has one of the lowest survival rates of any major cancer. The five-year relative survival rate is just 13%. Dr. Paul Oberstein of NYU Langone’s Perlmutter Cancer Center spoke with The Post about what Rasonque (daraxonrasib) treatment means for pancreatic research, earlier-stage disease and the future of treatment.
An experimental oral treatment, acting on a genetic mutation involved in the development of pancreatic cancer, has shown promising results in patients with metastatic disease previously treated with chemotherapy. Early clinical data indicate a reduction in tumours in a part of the patients and support further research in a phase III study.
The median survival goes from 6.7 to 12.4 months, but it is necessary to clarify: the results concern only second-line patients, i.e. already treated with a first chemotherapy. The studies to extend the use of the drug to other patients are still ongoing. The issues related to costs and access to treatment in Italy remain open. The opinion of Professor Giampaolo Tortora (Gemelli)
A pill-based treatment resulted in tumor reduction in 41% of patients with metastatic pancreatic cancer included in a clinical study.
Pancreatic cancer continues to be one of the greatest challenges in Oncology.
An experimental oral treatment, acting on a genetic mutation involved in the development of pancreatic cancer, demonstrated promising results in patients with metastatic disease previously treated with chemotherapy.
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
